2-Amino-¦Á-(Methoxyimino)-4-Thiazoleacetic Acid

Scale-up of acylation reactions employing 2-amino-α-(methoxyimino)-4-thiazoleacetic acid as the active ester or derived mixed anhydride typically proceeds in a 5,000 L to 10,000 L glass-lined reactor fitted with a retreat-curve impeller operating at 80–120 rpm. The acid is commonly pre-activated with 2-mercaptobenzothiazole (MBT) and dicyclohexylcarbodiimide (DCC) in dichloromethane or ethyl acetate at –5 °C to 0 °C to generate the crystalline 2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetic acid benzothiazolyl thioester. In this form, the moisture content of the isolated thioester is held below 0.15% (Karl Fischer titration) to prevent hydrolysis of the active thioester bond during storage prior to coupling. Coupling to the 7-aminocephalosporanic acid (7-ACA) nucleus is executed in a mixed aqueous-organic medium, frequently tetrahydrofuran/water (4:1 v/v), with triethylamine as the proton acceptor; the pH is maintained at 6.8–7.2 (glass electrode, calibrated at reaction temperature) because deviation above pH 7.8 accelerates β-lactam ring opening. During the coupling stage, the temperature is ramped from 0 °C to 15 °C over 90–120 min, and the reaction end-point is determined by HPLC showing residual 7-ACA ≤ 0.5% area normalization. The subsequent acid hydrolysis of the acetoxymethyl group at C-3 to afford the 3-hydroxymethyl cefotaxime intermediate requires stopping the addition of methanesulfonic acid precisely when the desacetyl impurity reaches 2.0%, as excessive exposure leads to lactone formation. Final precipitation is induced by adjusting the aqueous concentrate to pH 3.2–3.5 with dilute ammonia, followed by filtration through a 0.5 µm absolute-rated bag filter and washing with chilled water for injection (≤4 °C) to remove unreacted triethylamine hydrochloride. Vacuum drying at 35 °C and ≤10 mbar for 12 h consistently delivers cefotaxime acid with a residual solvent profile complying with ICH Q3C and an (E)-isomer content of less than 1.0% when analyzed by a European Pharmacopoeia monograph method using a C18 column with sodium phosphate/acetonitrile mobile phase.

What dictates the choice between active ester and acid chloride routes for 2-amino-α-(methoxyimino)-4-thiazoleacetic acid activation in ceftriaxone disodium synthesis?

The acid chloride route, which deploys phosphorus pentachloride or thionyl chloride in the presence of N,N-dimethylformamide as a catalyst at –15 °C to –10 °C, generates the acid chloride hydrochloride of the methoxyimino acid, but industrial batches adopting this chemistry encounter a recurring bottleneck: the liberation of sulfur dioxide and hydrogen chloride creates a corrosive headspace that attacks graphite rupture discs and necessitates a Hastelloy C-276 dip pipe. In contrast, the active thioester approach using MBT/DCC eliminates corrosive gaseous by-products but introduces a purification step for dicyclohexylurea removal, which if incomplete can precipitate as fine needles in the final crystallization of ceftriaxone disodium hemiheptahydrate and cause particulate failure under USP <788> (light obscuration particle count test). The condensation with 7-amino-3-[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-1,2,4-triazin-3-yl)thiomethyl]cephalosporanic acid (7-ACT) is performed in a water-miscible solvent system at a weight ratio of 1:1.2 (nucleus:active ester), with the reaction mixture held at 15–20 °C for not less than 4 h under nitrogen sparging to suppress oxidative color body formation. A critical in-process control point is the pH adjustment during the aqueous workup: sodium bicarbonate is added in aliquots to reach pH 5.5–6.0 before extraction with methylene chloride to remove uncondensed active ester degradation products. Failure to maintain a temperature below 25 °C during this extraction results in increased levels of the anti-isomer of ceftriaxone, which is restricted to ≤0.8% by the Ph.Eur. monograph 10.0. During the final conversion to the disodium salt, the addition of sodium 2-ethylhexanoate solution to a ceftriaxone acid acetone solvate is metered at a rate of 0.5 L/min into a 1,500 L vessel with a pitched-blade turbine to avoid localized supersaturation that yields hollow crystals with poor filtration characteristics. The resulting ceftriaxone disodium is filtered on a Nutsche filter-dryer, washed with acetone (0.5% w/w water), and vacuum-dried at 40 °C to a water activity of 0.35–0.45 measured at 25 °C to preserve the hemiheptahydrate stoichiometry.

Cefodizime: Dual activation strategy and chromatographic separation of the syn-isomer

Manufacturing cefodizime acid integrates 2-amino-α-(methoxyimino)-4-thiazoleacetic acid as the syn-oxime configured building block, which is first converted to the 1-hydroxybenzotriazole active ester in acetonitrile at –10 °C using N,N'-diisopropylcarbodiimide (DIC) in place of DCC to facilitate urea by-product solubility. The coupling partner, 7-amino-3-[(5-carboxymethyl-4-methylthiazol-2-yl)thiomethyl]-3-cephem-4-carboxylic acid, is suspended in a mixture of methylene chloride and N-methylpyrrolidone (8:1 v/v) at 4 °C; triethylamine addition is controlled by a pH-stat setpoint of 7.0 ± 0.2 over a 3 h period. One of the persistent scale-up problems specific to this intermediate is the epimerization at the C-7 position under basic conditions. The methoxyimino group directs the stereochemistry at the adjacent carbon as the syn (Z) configuration, but exposure to amine bases at temperatures above 8 °C for more than 30 min promotes conversion to the anti (E) diastereomer. Production-scale batches therefore employ a jacketed stirred-tank cascade: the acylation is performed in Reactor A at 5 °C, and upon completion verified by in-line FTIR monitoring of the β-lactam carbonyl stretch at 1780 cm⁻¹, the reaction mass is transferred within 8 min via a cooled stainless steel transfer line to a quenching vessel containing dilute hydrochloric acid at 2 °C. Purification of crude cefodizime acid from the E-isomer requires a preparative HPLC system with a 150 mm diameter dynamic axial compression column packed with C18 silica, eluting with a phosphate buffer-methanol gradient. The overall yield from the active ester to isolated cefodizime acid meeting JP XVIII specifications (purity ≥ 98.5%, single impurity ≤ 1.0%) is typically 72–78% on a pilot scale.

Production of ceftizoxime pivots on the direct acylation of the 7-amino-3-nor-cephalosporanic acid nucleus with the thiazoleacetic acid derivative, but the absence of a substituent at the C-3 position makes this cephem nucleus exceptionally sensitive to oxidative degradation and discoloration. Before coupling, the nucleus is dissolved in dimethylacetamide containing 0.1% w/w sodium metabisulfite as an antioxidant and cooled to –5 °C. The acid is introduced as a pre-formed mixed anhydride with pivaloyl chloride and N-methylmorpholine in dry tetrahydrofuran; the anhydride formation temperature is held strictly between –20 °C and –15 °C and the addition time must not exceed 25 min, as repeated lab-scale studies corroborate that mixed anhydride decomposition becomes autocatalytic above –10 °C and leads to a detectable exotherm exceeding 1.5 °C/min that triggers the reactor's cooling alarm setpoint. Once the mixed anhydride solution is transferred to the nucleus slurry, the temperature is allowed to rise to 5 °C over 60 min and then maintained for an additional 2 h. The workup involves dilution with water adjusted to pH 2.5 with sulfuric acid, extraction of unreacted acid with isobutyl acetate, and subsequent pH adjustment of the aqueous phase to the isoelectric point of ceftizoxime at approximately 3.0. The crystalline product isolated in a horizontal peeler centrifuge (basket speed 900 rpm, filter cloth ETFE 180 µm) typically exhibits a bulk density of 0.35–0.45 g/mL, which influences die filling consistency during subsequent dry powder filling into vials. Drying in a double-cone rotary vacuum dryer at 30 °C/10 mbar for 16 h reduces methanol content (a side-product of methoxyimino hydrolysis) to below 300 ppm, which is the limit defined by the in-house drug substance specification derived from ICH Q3C Class 2 solvent residual levels for methanol.

Ceftiofur hydrochloride and its crystalline changes under mechanoactivation

In veterinary medicine, 2-amino-α-(methoxyimino)-4-thiazoleacetic acid provides the critical side chain for ceftiofur, a third-generation cephalosporin approved for respiratory disease in cattle and swine. The synthetic pathway diverges from human medicines at the point of intermediate purification: trimethylsilyl protection of the acid's amino group is employed rather than benzyl protection, using hexamethyldisilazane and trimethylchlorosilane in toluene at 50 °C under anhydrous conditions to form the N-silylated derivative, which then reacts with furoyl chloride to afford the N-furoyl-protected side chain. This protected acid is activated as the acid chloride using oxalyl chloride in tetrahydrofuran with 1 drop of pyridine per liter of solvent, a catalytic quantity determined by the moisture content of the solvent batch, typically ≤100 ppm. Acylation of 7-amino-3-[(2-furoylthiomethyl)]-3-cephem-4-carboxylic acid is performed in dichloromethane at –30 °C, a temperature achieved with a liquid nitrogen indirect cooling loop, because the unprotected thioester group on the nucleus is prone to cleavage at higher temperatures. The ceftiofur hydrochloride isolated after cleavage of the silyl and furoyl groups is often a micronized powder with a particle size D50 of 5–10 µm designed for suspension formulation in an oily vehicle. However, long-term stability studies at 40 °C/75% RH reveal that the hydrochloride salt can undergo partial hydrolysis to ceftiofur free acid, producing a visible caking in the powder that is directly measurable as a shift in the powder X-ray diffraction pattern with a new peak appearing at 2θ = 14.2°. Manufacturing facilities processing this compound frequently equip air-jet milling lines with inline dew-point monitors set to alarm at –30 °C dew point to avoid moisture pickup above 0.2% in the micronization chamber. A validated limit for the 2-amino-α-(methoxyimino)-4-thiazoleacetic acid residual free acid impurity in the final ceftiofur hydrochloride drug substance is set at ≤0.05%, determined by ion-pair HPLC with a detection wavelength of 254 nm, because of the potential for this small molecule hapten to elicit a sensitization response in treated animals.

Compounds requiring the methoxyimino acid as a carrier-linked pro-moiety

Beyond direct cephalosporin acylation, 2-amino-α-(methoxyimino)-4-thiazoleacetic acid is used as a carrier-linked pro-moiety for prodrug synthesis, most notably in cefetamet pivoxil. The acid is first transformed into the corresponding 2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl chloride hydrochloride, and then condensed with 7-amino-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid in aqueous acetone at pH 5.5–6.5. Once the cephalosporin acid is formed, it is esterified with pivaloyloxymethyl bromide in N,N-dimethylformamide with potassium carbonate as a base at 20–25 °C, producing cefetamet pivoxil. The esterification step uses 1.3 molar equivalents of the bromide relative to the acid, and the reaction mixture is monitored by TLC (silica gel GF254, ethyl acetate/hexane 1:1) until the acid spot disappears. After aqueous workup and extraction into ethyl acetate, the organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The product is crystallized from isopropanol/water 4:1 at 0–5 °C, yielding needles with a melting point of 128–130 °C (dec.) as specified in the International Pharmacopoeia monograph. Residual 2-amino-α-(methoxyimino)-4-thiazoleacetic acid in the final prodrug must be below 0.03% because the free acid is a hydrolysis marker that accelerates decomposition of the ester in the presence of trace moisture. A validated limit test by gradient RP-HPLC (C8 column, 150 × 4.6 mm, 5 µm; mobile phase A: 0.05M phosphate buffer pH 3.0, mobile phase B: acetonitrile; gradient 10% B to 70% B in 25 min) is used for release testing, with a limit of quantitation of 0.01% for the free thiazoleacetic acid impurity.

The condensation of the methoxyimino acid derivative with 7-amino-3-[(1-methyl-1H-tetrazol-5-yl)thiomethyl]-3-cephem-4-carboxylic acid to produce cefepime-related intermediates requires a departure from conventional polar aprotic solvents. A suspension of the 7-amino nucleus in dimethylacetamide containing 10% w/v lithium chloride at 25 °C leads to complete dissolution of the nucleus in 15 min through chloride ion disruption of internal hydrogen bonding. The thioester of 2-amino-α-(methoxyimino)-4-thiazoleacetic acid and 2,2'-dithiobis(benzothiazole) is then added in one portion. The presence of lithium chloride not only solubilizes the nucleus but also attenuates the rate of acylation to a controllable pseudo-first-order rate constant of approximately 0.012 min⁻¹ at 20 °C, as determined by UV spectroscopy monitoring at 270 nm (absorbance increase due to benzothiazolethiolate release). This moderated kinetics prevents runaway exotherms in reactor sizes above 2,000 L. Upon completion, the reaction is quenched into dilute hydrochloric acid at 5 °C, and the precipitated cephalosporanic acid is collected and dried. The methanol generated from any methoxyimino hydrolysis is removed by azeotropic distillation with acetonitrile under reduced pressure (400 mbar, jacket temperature 40 °C) until headspace GC analysis shows methanol ≤ 500 ppm. The final cefepime intermediate dihydrochloride monohydrate must meet a specification for residual benzothiazolethiol (MBT) of ≤0.1%, as MBT forms insoluble complexes with metals used in filling line parts and stains product contact surfaces, requiring frequent cleaning-in-place cycles documented in the site's master batch records.